In short
A new clinical trial is exploring the potential of Galinpepimut-S (GPS), a novel drug, as a maintenance therapy for patients with acute myeloid leukemia (AML) who have achieved a second or later complete remission. This phase 3 study aims to compare the effectiveness and safety of GPS to the best available treatment options. The trial focuses on improving overall survival and leukemia-free survival for AML patients, offering hope for better long-term outcomes in this challenging disease.
At a glance
- Drug Name
- Galinpepimut-S (GPS)
- Study Type
- Phase 3, Randomized, Open-Label
- Condition
- Acute Myeloid Leukemia (AML) in second or later complete remission
- Primary Objective
- Compare efficacy of GPS to Best Available Treatment on overall survival
- Secondary Objectives
- Assess safety, leukemia-free survival, and minimal residual disease
- Administration
- Subcutaneous injection
- Maximum Daily Dose
- 0.8 mg
- Maximum Total Dose
- 24.8 mg
- Treatment Duration
- Up to 36 months
- Key Eligibility
- Adults with AML in CR2/CRp2 or later, not candidates for allogeneic stem cell transplant
What is Galinpepimut-S?
Galinpepimut-S, also known as GPS, is an investigational drug being studied for the treatment of acute myeloid leukemia (AML). It is a complex medication composed of multiple peptides (small protein fragments) with the following scientific names: TYR-MET-PHE-PRO-ASN-ALA-PRO-TYR-LEU, SER-GLY-GLN-ALA-TYR-MET-PHE-PRO-ASN-ALA-PRO-TYR-LEU-PRO-SER-CYS-LEU-GLU-SER, ARG-SER-ASP-GLU-LEU-VAL-ARG-HIS-HIS-ASN-MET-HIS-GLN-ARG-ASN-MET-THR-LYS-LEU, and PRO-GLY-CYS-ASN-LYS-ARG-TYR-PHE-LYS-LEU-SER-HIS-LEU-GLN-MET-HIS-SER-ARG-LYS-HIS-THR-GLY.
Target Condition: Acute Myeloid Leukemia
Galinpepimut-S is specifically being studied for patients with acute myeloid leukemia who are in second or later complete remission (CR2) or second or later complete remission with incomplete platelet recovery (CRp2). This means the drug is intended for AML patients who have: Achieved remission (significant reduction or disappearance of cancer) after their initial treatment Experienced a relapse (return of the cancer) Achieved a second remission through additional treatment Acute myeloid leukemia is a type of blood cancer that affects the bone marrow, where blood cells are produced. In AML, abnormal white blood cells grow rapidly, interfering with the production of normal blood cells.
How Galinpepimut-S Works
While the exact mechanism is not fully described in the provided information, Galinpepimut-S is likely designed to work as an immunotherapy. Immunotherapies help the body's immune system recognize and fight cancer cells. The complex peptide structure of GPS may help stimulate the immune system to target specific markers found on AML cells, potentially preventing or delaying the return of the cancer after remission.
Clinical Trial Overview
Galinpepimut-S is currently being studied in a Phase 3 clinical trial. This is an advanced stage of research that aims to confirm the drug's effectiveness and safety in a larger group of patients. The study is designed as follows: Study Type: Randomized, open-label study Main Objective: To compare the efficacy of GPS to the Investigator's choice of Best Available Treatment (BAT) on overall survival in AML patients in CR2/CRp2 Secondary Objectives: Assess safety and tolerability of GPS Evaluate other efficacy measures such as Leukemia Free Survival (LFS) and minimal residual disease Examine the effect of prior stem cell transplantation on GPS efficacy
Eligibility Criteria
To participate in this study, patients must meet specific criteria. Some key eligibility factors include: Age 18 or older Diagnosed with AML and in second or later complete remission Not currently eligible for stem cell transplant Adequate recovery from previous treatments Sufficient liver and kidney function There are also several exclusion criteria, such as certain prior treatments, other active cancers, or specific medical conditions that would prevent participation.
Potential Benefits
The primary goal of this study is to determine if Galinpepimut-S can improve overall survival for AML patients compared to current best available treatments. Other potential benefits being evaluated include: Leukemia Free Survival (LFS): The length of time patients remain in remission without signs of leukemia returning Minimal Residual Disease (MRD): Detecting very small amounts of remaining cancer cells that standard tests might miss Improved survival rates at 6, 9, and 12 months after treatment
Administration and Dosage
Galinpepimut-S is administered as a subcutaneous injection (an injection under the skin). The maximum daily dose being studied is 0.8 mg, with a maximum total dose of 24.8 mg over a treatment period of up to 36 months. The exact dosing schedule and duration may vary based on individual patient factors and response to treatment.
Safety Considerations
As with any investigational treatment, there are potential risks and side effects to consider: Patients with a history of severe allergic reactions to similar substances (like Montanide or certain growth factors) are not eligible for the study The treatment may affect the immune system, so patients with autoimmune diseases or immunodeficiencies may not be suitable candidates Pregnant or breastfeeding women are excluded from the study due to unknown effects on fetal development As with any cancer treatment, there may be unexpected side effects that will be closely monitored during the trial It's important to discuss all potential risks and benefits with your healthcare provider if you're considering participating in this or any clinical trial.